These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 17223448)

  • 1. Democrats on drugs.
    Lancet; 2007 Jan; 369(9556):79. PubMed ID: 17223448
    [No Abstract]   [Full Text] [Related]  

  • 2. Ties between regulators and business are attacked after politician takes top job in industry.
    Lenzer J
    BMJ; 2005 Jan; 330(7482):60. PubMed ID: 15637359
    [No Abstract]   [Full Text] [Related]  

  • 3. Pharma allowed to make own genetics.
    Owens J
    Nat Rev Drug Discov; 2005 Jul; 4(7):530. PubMed ID: 16075483
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory evaluation of biotechnology drugs: current trends in the United States.
    Sobel S
    Bioprocess Technol; 1991; 13():499-511. PubMed ID: 1367148
    [No Abstract]   [Full Text] [Related]  

  • 5. Off-label promotion.
    Somberg J
    Am J Ther; 2006; 13(5):387. PubMed ID: 16988530
    [No Abstract]   [Full Text] [Related]  

  • 6. The FDA's critical path initiative: a brief introduction.
    Coons SJ
    Clin Ther; 2009 Nov; 31(11):2572-3. PubMed ID: 20110002
    [No Abstract]   [Full Text] [Related]  

  • 7. Drugs bill to rein in profits.
    Gershon D
    Nature; 1994 Mar; 368(6470):381. PubMed ID: 8133874
    [No Abstract]   [Full Text] [Related]  

  • 8. The learned intermediary doctrine: past, present and future.
    Alsobrook HB
    Leg Med; 1994; ():269-80. PubMed ID: 7830482
    [No Abstract]   [Full Text] [Related]  

  • 9. NIH urged to cap profits made on publicly funded research.
    Macilwain C
    Nature; 2000 Jul; 406(6791):5. PubMed ID: 10894508
    [No Abstract]   [Full Text] [Related]  

  • 10. US policy may encourage counterfeit drugs.
    Bouchie A
    Nat Biotechnol; 2003 Feb; 21(2):121. PubMed ID: 12560826
    [No Abstract]   [Full Text] [Related]  

  • 11. Patents: a threat to innovation?
    Manocaran M
    Science; 2010 Jan; 327(5961):31-2; author reply 32. PubMed ID: 20044557
    [No Abstract]   [Full Text] [Related]  

  • 12. A generic problem.
    Hanauer SB
    Nat Clin Pract Gastroenterol Hepatol; 2006 Dec; 3(12):649. PubMed ID: 17130869
    [No Abstract]   [Full Text] [Related]  

  • 13. The resurgence of indefiniteness?
    Burton CA
    Pharm Pat Anal; 2016; 5(1):1-3. PubMed ID: 26674975
    [No Abstract]   [Full Text] [Related]  

  • 14. Toward allocative efficiency in the prescription drug industry.
    Guell RC; Fischbaum M
    Milbank Q; 1995; 73(2):213-30. PubMed ID: 7776946
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Raising the bar for market authorisation of new drugs.
    Naci H; Cylus J; Vandoros S; Sato A; Perampaladas K
    BMJ; 2012 Aug; 345():e4261. PubMed ID: 22872693
    [No Abstract]   [Full Text] [Related]  

  • 16. Tripping over trips and the global HIV/AIDS epidemic: legislation and political decisions in Brazil and the United States.
    Emilio AB
    J Contemp Health Law Policy; 2011; 28(1):57-85. PubMed ID: 22292321
    [No Abstract]   [Full Text] [Related]  

  • 17. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
    McCabe AR
    Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
    [No Abstract]   [Full Text] [Related]  

  • 18. PLIVA v. Mensing: generic consumers' unfortunate hand.
    Lee SB
    Yale J Health Policy Law Ethics; 2012; 12(2):209-63. PubMed ID: 23175916
    [No Abstract]   [Full Text] [Related]  

  • 19. US aims to tighten rules on direct-to-consumer drug ads.
    Vastag B
    Nat Biotechnol; 2007 Mar; 25(3):267. PubMed ID: 17344868
    [No Abstract]   [Full Text] [Related]  

  • 20. Nevada law aims to halt drug diversion by wholesalers.
    Young D
    Am J Health Syst Pharm; 2002 Jan; 59(2):103-4. PubMed ID: 11826557
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.